A novel in vitro model was recently developed in our laboratories for the prediction of magnitude of clinical pharmacokinetic drugdrug interactions (DDIs), based on reversible hepatic cytochrome P450 (P450) inhibition. This approach, using inhibition data from human hepatocytes incubated in human plasma, and quantitative P450 phenotyping data from hepatic microsomal incubations, successfully predicted DDIs for 15 marketed drugs with ketoconazole, a strong competitive inhibitor of CYP3A4/5, generally used to demonstrate a "worst-case scenario" for CYP3A inhibition. In addition, this approach was successfully extended to DDI predictions with the moderate competitive CYP3A inhibitor fluconazole for nine marketed drugs. In the current report, the general applicability of the model has been demonstrated by prospectively predicting the degree of inhibition and then conducting DDI studies in the clinic for an investigational CCR1 antagonist MLN3897, which is cleared predominantly by CYP3A. The clinical studies involved treatment of healthy volunteers (n ϭ 17-20), in a crossover design, with ketoconazole (200 mg b.i.d.) or fluconazole (400 mg once a day), while receiving MLN3897. Administration of MLN3897 and ketoconazole led to an average 8.28-fold increase in area under the curve of plasma concentration-time plot (AUC) of MLN3897 at steady state, compared with the 8.33-fold increase predicted from the in vitro data. Similarly for fluconazole, an average increase of 3.93-fold in AUC was observed for MLN3897 in comparison with a predicted value of 3.26-fold. Thus, our model reliably predicted the exposure changes for MLN3897 in interaction studies with competitive CYP3A inhibitors in humans, further strengthening the utility of our in vitro model.
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Prediction of clinical DDIs using in vitro studies is one of the major challenges in the pharmaceutical industry. The main utility of such DDI predictions is to help foresee any safety issues anticipated from higher exposures and thus help design clinical trials with better safety. In some instances, clinical DDI studies can be avoided if no significant pharmacokinetic interaction is predicted. Traditionally, DDI predictions have been based on the ratio of the inhibitor concentration [I] and the enzyme inhibition constant K i ([I]/K i ratio) (Rostami-Hodjegan and Tucker, 2004; Ito et al., 2004; Obach et al., 2006; 2006 FDA draft guidance on DDI studies at http://WWW.FDA.gov/cder/ guidence/6695dft.html). Although this approach had some successes in predicting DDIs, reliability of predictions still remains a challenge (Blanchard et al., 2004; Cook et al., 2004; Ito et al., 2004; Bachmann 2006; Obach et al., 2006) . Difficulty remains both in estimating the physiological concentration of the inhibitor at the enzyme site and in reliably determining K i , which often is affected by the experimental conditions used. Factors such as the protein concentration in the incubation, the substrate of choice, and the enzyme source (Thummel and Wilkinson 1998; Galetin et al., 2006; Lu et al., 2008b) have all been shown to affect the K i determination. Because the value of [I] (the enzyme site free concentration) cannot be accurately assessed, scientists have used various alternative parameters to investigate what correlated well with in vivo observations for a selection of compounds. The results indicate that no uniform parameter could be used to predict interactions broadly. In our in vitro assays, we used human hepatocytes suspended in human plasma, with the plasma concentration of the inhibitors in the incubations being similar to the clinical C max of the inhibitor observed with standard dosing. The free concentration at the enzyme site would be same in the two systems (Lu et al., 2007 (Lu et al., , 2008a . Consequently, our model eliminates the need to determine the value of [I] and removes the dependence on the traditional, less desirable rule of [I]/K i ratio to predict magnitude of DDIs.
MLN3897 is a potent and selective antagonist of the C-C chemokine receptor-1 (CCR1). In a preclinical reaction phenotyping study, MLN3897 was determined to be cleared mainly by CYP3A, necessitating the conduct of clinical DDI studies based on the 2006 FDA draft guidance on DDI studies at http:// WWW.FDA.gov/cder/guidence/6695dft.html. In the present study, ketoconazole was coadministered with MLN3897 in healthy volunteers to assess the extent of inhibition with a strong CYP3A inhibitor. Fluconazole was then coadministered to evaluate and compare the magnitude of interaction in the presence of a moderate CYP3A inhibitor.
Materials and Methods
Reagents. Pooled human liver microsomes from 50 donors were purchased from XenoTech, LLC (Lenexa, KS). Cryopreserved human hepatocytes were purchased from In Vitro Technologies (Baltimore, MD) and AP Sciences Inc. (Baltimore, MD). 4-Hydroxytolbutamide, 4-hydroxymephenytoin, 1Ј-hydroxymidazolam, (S)-(ϩ)-(N)-(3)-benzylnirvanol (benzylnirvanol), and azamulin were purchased from BD Gentest (Woburn, MA). Phenacetin, acetaminophen, tolbutamide, dextromethorphan, dextrorphan, furafylline, sulfaphenazole, quinidine, fluconazole, midazolam, NADPH, and MgCl 2 were purchased from Sigma-Aldrich (St. Louis, MO). Human plasma was purchased from Bioreclamation Inc. (Hicksville, NY). (S)-Mephenytoin was purchased from BIOMOL Research Laboratories, (Plymouth Meeting, PA). MLN3897 was synthesized at Millennium Pharmaceuticals, Inc. (Cambridge, MA).
P450 Inhibition Determination in Human Hepatocytes. In vitro assays, such as the reaction phenotyping to obtain the relative P450 contribution values (fm) for MLN3897, the determination of P450 activity remaining (fA) in the presence of ketoconazole or fluconazole in human hepatocytes suspended in human plasma, and the calculation of predicted AUC changes from in vitro data were described in our previous reports (Lu et al., 2007 (Lu et al., , 2008a . In brief, to determine P450 enzyme activity remaining in the presence of inhibitors, the fA values, serially diluted ketoconazole or fluconazole in human plasma was added into human hepatocytes. After allowing 10 min of equilibration time, the P450 isozyme-specific substrates prepared in plasma were added to start 45-min incubations for assessing the P450 activity. The reactions were stopped by adding two volumes of acetonitrile containing 1 M carbutamide (internal standard). The samples were kept in a refrigerator for 30 min and then centrifuged at 3000g for 10 min. The supernatants were analyzed by liquid chromatography-tandem mass spectrometry for the amount of metabolites formed from the probe substrates. The percentage of metabolic activity remaining was calculated by comparing the P450 activities in samples with various concentrations of ketoconazole or fluconazole with their vehicle control. In parallel, extracellular plasma concentrations of ketoconazole or fluconazole were determined after hepatocytes were separated from the plasma using the oil layer separation technique after the 10-min equilibration (Shitara et al., 2003; Lu et al., 2008a) . These in vitro extracellular plasma concentrations and their corresponding fA values were used to pair with known clinical plasma C max values to perform DDI prediction.
Reaction Phenotyping of MLN3897 in Human Liver Microsomes Using P450-Selective Chemical Inhibitors. The relative P450 contributions to the hepatic metabolism of MLN3897 (fm) was determined using P450-selective chemical inhibitors. The concentrations of the inhibitor were determined previously in human liver microsomal incubations to produce more selective inhibition of a particular P450, meaning high inhibition toward the target P450 but less of cross-inhibition to other P450s. P450 probe substrates were also incubated in the study to determine the partial inhibition and cross reactivity of these inhibitors. The results from P450 probe substrate incubations were then used to calculate the inhibition of MLN3897 metabolism, assuming that it is subject to same degree of partial inhibition and cross-reactivity to these inhibitors as the probe substrates (Lu et al., 2007) . Specifically, human liver microsomes (25 l; final concentration of 0.5 mg/ml in 0.1 M potassium phosphate buffer, pH 7.4) were prewarmed in 96-well plates for 5 min at 37°C, in duplicate, with 25 l of MLN3897 or probe substrates (at their respective K m concentrations) and 25 l of P450-selective inhibitors prepared in the same buffer. The reactions were initiated by the addition of 25 l of NADPH/MgCl 2 in 0.1 M potassium phosphate buffer (final concentration of 2 and 3 mM, respectively) and incubated for 15 min. Acetonitrile (1%, final concentration) and dimethyl sulfoxide (0.1%) were used as solvent to increase compound solubility, and they have minimal effect on P450 activity. The reactions were terminated by the addition of 100 l of acetonitrile containing 1 M carbutamide as the internal standard (IS). After storing for 30 min in a refrigerator, the sample plates were centrifuged at 3000g for 10 min, and the supernatants were analyzed using liquid chromatography-mass spectrometry. The final concentrations of the respective P450-selective inhibitors and probe substrates were as follows: 100 M furafylline and 30 M phenacetin for CYP1A2; 5 M sulfaphenazole and 150 M tolbutamide for CYP2C9; 20 M benzylnirvanol and 100 M (S)-mephenytoin for CYP2C19; 5 M quinidine and 8 M dextromethorphan for CYP2D6; and 2 M azamulin and 50 M testosterone for CYP3A4. The method for calculation of AUC changes from the in vitro data (predicted DDI) using the equation shown under Results was described previously (Lu et al., 2007) .
Effect of Ketoconazole on Steady-State Pharmacokinetics of MLN3897. The ketoconazole and fluconazole-MLN3897 clinical DDI studies were carried out in accordance with the good clinical practice principles enunciated in the Declaration of Helsinki (revised version of Edinburgh, Scotland, 2000; Note of Clarification on Paragraph 29 added by the World Medical Association General Assembly, Washington, 2002) , and the International Conference on Harmonisation harmonized tripartite guideline regarding good clinical practice (E6 Consolidated Guidance, April 1996). The study was approved by the Institutional Review Board, and informed consent was obtained for each subject.
Because of the long plasma half-life of MLN3897, it was administered orally at a proposed efficacious dose of 10 mg once a day (QD) to 20 healthy subjects (10 males and 10 females), for 16 consecutive days (greater than five half-lives) (Fig. 1) to reach steady state. The mean age, height, and weight was 28 years, 171.3 cm, and 70.5 kg, respectively. The PK profile was measured on day 16. After a washout period (days 17-33), ketoconazole was administered at 200 mg b.i.d. from day 34 through day 58. MLN3897 coadministration was started on day 37 and continued through day 58. The extended dosing for MLN3897 (compared with period 1; 16 days preketoconazole dosing versus 22 days with ketoconazole) was to ensure achievement of a new steady state, accounting for the anticipated increase in half-life of MLN3897 when coadministered with P450 inhibitor ketoconazole. On day 58, the PK of MLN3897 was measured again. The ratio of AUC of MLN3897 administrated with ketoconazole over MLN3897 alone was calculated.
Effect of Fluconazole on Steady-State Pharmacokinetics of MLN3897 and Effect of MLN3897 on CYP3A Activity. A slightly modified study design was applied for the fluconazole DDI trial with 17 healthy subjects (11 males, 6 females; Fig. 2 ). The mean age, height, and weight was 33 years, 171.7 cm, and 74.6 kg, respectively. Because MLN3897 was tolerated at higher exposure when coadmin- jpet.aspetjournals.org istered with ketoconazole, on day 1, a calculated, loading dose of 30 mg QD of MLN3897 was given orally followed by 25 additional doses of 10 mg QD of MLN3897. The pharmacokinetics was measured on day 10. Fluconazole at 400 mg QD was then administered along with 10 mg of MLN3897 from day 12 to day 26. The PK of MLN3897 with coadministration of fluconazole was measured again on day 26, and the AUC ratio was determined to assess the magnitude of the DDI.
An initial part of this study had been constructed to evaluate whether MLN3897 had any effect on CYP3A activities. MLN3897, maintained at steady-state levels, and midazolam (2 mg QD), a selective CYP3A substrate, were concurrently dosed orally on day 0 (pre-MLN3897 dose) and day 11, and the PK profiles were compared.
Clinical Plasma Sample Analysis. Blood samples were collected at various time points and centrifuged at approximately 2500 rpm for approximately 15 min at 4°C to obtain plasma samples. Plasma samples were stored at or below Ϫ80°C within 1 h of collection. Samples were assayed for MLN3897 under good laboratory practice using a validated liquid chromatography coupled with tandem mass spectrometry method. Specifically, plasma samples (100 l) were processed using a liquid-liquid extraction procedure to isolate the analyte and the IS MLN3897-d6 from human plasma. The extracted samples were dried, reconstituted in 100 l of 50:50 mixture of acetonitrile and 5 mM ammonium hydroxide, and 15 l of the reconstituted solution was injected onto a Zorbax Extend-C18 column (2.1 ϫ 100 mm; 3.5 m) for analysis. The high-performance liquid chromatography separation was performed at a flow of 0.3 ml/min under a gradient elution mode with 5 mM ammonium hydroxide in water as mobile phase A and acetonitrile as mobile phase B. Each gradient analysis took approximately 4 min. The mass transitions used were m/z 533.4 3 236.3 for MLN3897 and m/z 539.4 3 236.3 for the IS. The dynamic range of the assay was 0.05 to 50 ng/ml. Plasma concentrations below the lower limit of quantification were treated as 0 ng/ml for calculation of summary statistics. Plasma concentrations above the upper limit of detection were reassayed after dilution for the concentrations to fall within the dynamic range of the assay.
Results
The CYP3A inhibition and cross-inhibition for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 by ketoconazole and fluconazole in human hepatocytes suspended in human plasma are presented in Tables 1 and 2 as a fraction of the activity remaining (fA). The relative contribution of the above-mentioned five major P450s toward the hepatic metabolism (fm) of MLN3897 is presented in Table 3 . MLN3897 is mainly cleared via hepatic metabolism (i.e., f m,hep ϭ 1), with negligible renal clearance (data not shown). The DDI prediction method described previously (Lu et al., 2007) involved two in vitro parameters, fA CYP and fm CYP , linked using the following equation:
where f m , hep is the fraction of clearance by hepatic metabolism, f m,cyp is the relative contribution of an individual P450 to the total metabolism of the compound (without inhibitor), and fA CYP is the fraction of enzyme activity remaining in the presence of the inhibitor. f other is the fraction of clearance by other routes such as renal or biliary excretion (f m ϩ f other ϭ 1). Experimental or clinical information of the effects of the inhibitor on the bioavailability across gastrointestinal tract (FgЈ/Fg) are generally not available (Galetin and Houston, 2009 ); therefore, this term was not included in our calculations. To assess the worst-case scenario of interaction, the clinical maximum plasma concentration of the inhibitor (C max ) was used to calculate the fA values. With these two simplifications, the latter step may compensate for the Figure 3 shows the steady-state mean plasma concentration increase of MLN3897 in both male and female subjects (total n ϭ 20) before and after multiple days of treatment with 200 mg b.i.d. of ketoconazole. There was little difference between the concentration-time profiles in male and female subjects, in agreement with the literature that gender differences in humans are minimal (Greenblatt and von Moltke, 2008) . However, an over 8-fold increase in MLN3897 AUC was observed in both groups, relative to their MLN3897 given alone groups. Figure 4 presents the daily trough concentration of MLN3897 with and without coadministration of ketoconazole. The data show MLN3897 reaches steady-state concentrations in 10 to 14 days, and longer time is required after ketoconazole coadministration. Table 4 summarizes the main pharmacokinetic parameters. Upon coadministration with ketoconazole, increases in AUC, C max , and C min at the steady state were 8.28-, 7.39-, and 9.27-fold, respectively. Figure 5 presents the individual AUC increases upon coadministration for the 20 subjects. The AUC change ranged from 4.5-to 13.0-fold.
A summary of the main pharmacokinetics parameters for the MLN3897-fluconazole DDI study (n ϭ 17) is shown in Table 5 . The mean MLN3897 AUC change upon coadministration of fluconazole was 3.93-fold with individual variation from 2.5-to 7.3-fold. The increase of C max and C min at the steady state was at the similar level (3.51-and 4.98-fold, respectively). The PK profile of MLN3897 at steady state before and after coadministration of fluconazole is shown in Fig. 6 .
Part of this clinical DDI study is designed to access whether repeated dosing of MLN3897 would affect the CYP3A activity. The PK profiles (data not shown) of midazolam pre-and post-MLN897 treatment showed no CYP3A activity change, as expected. Because the evaluation of MLN3897 as a perpetrator of CYP3A-mediated DDI is not the focus of this article, no further discussion is included.
Discussion
The primary objectives of this study were to investigate the potential CYP3A inhibitor-mediated DDI risk for an investigational CCR1 antagonist and CYP3A substrate MLN3897 in healthy volunteers and to demonstrate an in vitro-in vivo correlation using a recently proposed novel in vitro prediction model (Lu et al., 2007 (Lu et al., , 2008a . In our DDI prediction model, inhibitors such as ketoconazole or fluconazole were incubated with human hepatocytes in 100% human plasma to construct concentration-P450 inhibition titration curves under conditions closely resembling those in vivo. At equilibrium, the extracellular (plasma) concentrations of the inhibitor were measured after separating the plasma from hepatocytes. Matching the extracellular plasma concentration in vitro with the plasma C max found in in vivo study then provided the extent of inhibition of various P450s from the titration TABLE 1 P450 activity remaining in human hepatocytes in the presence of ketoconazole in human plasma Ketoconazole was equilibrated with human hepatocytes in human plasma to allow nonspecific binding. After equilibration, the extracellular concentration of ketoconazole was measured. The remaining P450 activities in hepatocytes (fA) were also determined using the probe substrates. Keto, ketoconazole. a fA (%), fraction of enzyme activity remaining in the presence of ketoconazole inhibition.
TABLE 2
Effect of fluconazole on P450 activity remaining in human hepatocytes suspended in human plasma
Fluconazole was equilibrated with human hepatocytes in human plasma to allow nonspecific binding. After equilibration, the extracellular concentration of fluconazole was measured. The remaining P450 activities in hepatocytes (fA) were also determined using the probe substrates. Adapted from Lu et al. (2008a) . Lu et al., 2008a) . A similar approach was applied to fluconazole with nine marketed drugs, where a good DDI prediction was demonstrated, with r 2 ϭ 0.71 (Lu et al., 2008b) . Three parameters used in this model are f m,hep , fm CYP , and fA CYP . The f m,hep is considered to be unity based on the human absorption, distribution, metabolism, and excretion study, where MLN3897 was cleared mainly through metabolism. The fm CYP was determined by quantitative P450 phenotyping. As discussed previously (Lu et al., 2007) , fA was calculated by intrapolation of the two closely measured fA values from the inhibition titration curves in hepatocyte incubations, covering the in vivo C max value of the inhibitor. For the model, at the reported C max of 10 M ketoconazole after 200 mg b.i.d. (Pelkonen et al., 1998) , the fA values for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 were calculated to be 0.864, 0.739, 0.604, and 0.006, respectively. CYP2D6 was not inhibited by ketoconazole at physiologically relevant concentrations. For fluconazole, at the reported C max of 69.2 M at 400-mg QD dose (Brunton et al., 2006) , the fA values were calculated to be 0.308, 0.133, and 0.203 for CYP2C9, CYP2C19, and CYP3A4, respectively. CYP1A2 and CYP2D6 were not inhibited by fluconazole. MLN3897 is being investigated for chronic oral administration to treat inflammatory diseases. To assess the maximal effect of CYP3A inhibition on MLN3897, administration of MLN3897 until steady state was reached was necessary. Because MLN3897 has a half-life of approximately 3 to 4 days, the steady state was expected in 16 days (four to five half-lives). In the presence of an inhibitor, the half-life of MLN3897 was expected to be prolonged; therefore, the coadministration of MLN3897 and ketoconazole was extended out to 22 days to ensure achievement of steady state. A similar time frame was applied for a washout period.
Coadministration of the CYP3A substrate MLN3897 with a strong CYP3A inhibitor, ketoconazole, resulted in the predicted elevation (8.33-fold; as predicted from the in vitro model) of steady-state MLN3897 AUC and represents the most extreme inhibition likely to be seen with clinically used CYP3A inhibitors. Fluconazole is a moderate CYP3A inhibitor and also inhibits other P450s, such as CYP2C9 and CYP2C19 (Venkatakrishnan et al., 2000) . The DDI study jpet.aspetjournals.org
using fluconazole illustrates what would be expected when a moderate CYP3A inhibitor is used with MLN3897 (which has no CYP2C9 or CYP2C19 contributions to its clearance). Because the observed greater than 8-fold elevation of exposure to MLN3897 was well tolerated in healthy subjects, a loading dose design was applied in the MLN3897-fluconazole DDI study to reduce the study time needed to reach the steady state. The pharmacokinetic parameters of MLN3897 determined after administration of a 30-mg loading dose of MLN3897, followed by 10 mg QD administration of MLN3897 over 10 days were comparable with those observed in the ketoconazole study. The AUC increase of MLN3897 with fluconazole was 3.93-fold, an increase closely predicted (3.26-fold) by our in vitro model. In summary, the clinical drug interaction studies of MLN3897 with ketoconazole and fluconazole yielded exposure increases for MLN3897, at steady state, that were predicted closely by our in vitro model. The model is not dependent on the traditional, ambiguous, and unreliable [I]/K i method. The DDI study for fluconazole was an "adaptive" design based on ketoconazole data, and allowed subjects to reach the steady state faster through the safe use of a loading dose. The predicted power of this simple in vitro model is further validated by the current studies. Such dependable predictions are expected to benefit clinical trials because any increased pharmacodynamic or side effects that are linked to pharmacokinetics can be anticipated. If necessary, doses can be adjusted to stay within a desired plasma range.
